• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Grifols Therapeutics Plans $210 Million Expansion In Clayton, North Carolina

Grifols Therapeutics Inc. plans a $210 million expansion on its 240-acre campus near Clayton, North Carolina. The Spain-based leader in plasma-derived medicine expects to create 250 jobs here over the coming decade.

The expansion by Grifols will consist of two new plants. One will be a fractionation facility of approximately 100,000 square feet with an annual output of six million liters. The second will be a 120,000-sq.-ft purification facility for the production of intravenous immunoglobulin.

As an incentive, Johnston County Board of Commissioners approved a 10- year incentive package. “Our county is proud to take its partnership with this leading biotech company to an exciting new level,” said Tony Braswell, Chairman of Johnston County’s Board of Commissioners. As Grifols meets its projections on capital investment and job creation, the county will grant up to $1,277,640 annually to the company for 10 years."

“Economic development, when it takes place at this level, is all about partnerships, and it is crucial that the county be a good partner. That means being prepared to share part of the risks as well as the rewards that will grow from this,” he added.

Founded in Barcelona in 1940, Grifols is a global leader in the fields of transfusion, blood banking, protein therapeutics and laboratory analysis. “Grifols is one of the leading global companies in the manufacture of plasma based medicines with a direct presence in 30 countries and sales in over 100 countries,” said Sergi Roura, president of Grifols Therapeutics. “The decision to invest in new facilities at Clayton is a result of expected growth in demand for our products, the significant presence that Grifols already has in North Carolina, and the favorable business environment we find in Johnston County.”

The company’s presence in Johnston County grew from its 2010 acquisition of Talecris. It has since invested heavily here, doubling the size of its plasma production facility and growing its workforce to approximately 1,650. Grifols’ latest expansion comes just one week after officials with Novo Nordisk broke ground on a $1.8 billion bio-manufacturing plant that will produce the active ingredient for the Denmark-based company’s insulin products. State, local and company leaders announced those plans last August.

“Johnston County has emerged as a major destination for bio-manufacturing jobs and investment,” said Chris Johnson, Director of the Johnston County Office of Economic Development. “The growing presence of companies like Grifols and Novo Nordisk forms a solid foundation for the county’s manufacturing economy, which keeps our population growing, our small business community vibrant and our tax-base strong. Along with the economic advantages these global companies bring is a level of community engagement that reaches into our schools, civic groups and neighborhoods in a very positive way. This is a great day for Johnston County.”

Exclusive Research